drugset / Trial / NCT04225221

Neurobiology of Bulimia Nervosa

NCT04225221

RandomizedCrossoverDouble-blindBasic science

Summary

This pilot study experimentally manipulates ovarian hormones to examine the direct impact of estrogen (E2) and progesterone (P4) on binge eating symptom burden and the behavioral reward response in women with bulimia nervosa (n=15). This is completed by taking medications that change ovarian hormone levels. This line of research could lead to the development of pharmacological interventions developed to target specific areas of the brain, brain receptors, or pathways identified to be involved in the mechanism underlying ovarian hormone change and binge eating.

Timeline

Start
2020-02-24
Primary completion
2022-04-04
Completion
2022-04-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Estradiol Other / unclassified 2 mg Oral
Subject Progesterone Other / unclassified 200 mg Oral
Background Leuprolide Other / unclassified 3.75 mg Intramuscular

Indications